Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
224 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (9)

Medical Condition

  • Show all (1221)
  • Addiction (16)
  • Allergy, Asthma, & Immunology (13)
  • All of Us Research Program - NIH (1)
  • Autoimmune Disorders (28)
  • Blood Disorders (18)
  • Bone & Muscle (10)
  • Cancer (102)
    • Brain Cancer (3)
    • Breast Cancer (13)
    • Gastrointestinal (2)
    • Gynecologic Cancer (30)
    • Kidney Cancer (1)
    • Leukemia (9)
    • Liver Cancer (2)
    • (-) Lung Cancer (4)
    • Lymphoma (10)
    • Multiple Myeloma (2)
    • Pancreatic Cancer (2)
    • Prostate Cancer (3)
    • Sarcoma (2)
    • Skin Cancer (2)
    • (-) Solid Tumors (4)
  • Child Development (4)
  • COVID-19 (Coronavirus) (36)
  • Critical Illness (1)
  • Diabetes (21)
  • Ear, Nose and Throat (12)
  • Endocrine & Metabolic Disease (12)
  • Eye (7)
  • Gastrointestinal and Digestive Diseases (26)
  • Hair and Skin Disorders (3)
  • Headaches (5)
  • Healthy Volunteers (187)
  • Heart Disease (130)
  • Infectious Disease (48)
  • Insomnia (3)
  • Kidney Disease (12)
  • Liver Disease (52)
  • Lung Disease (31)
  • Meniere's Disease (1)
  • Neurological Disorders (126)
  • Nutrition (5)
  • Obesity (9)
  • Obstetrics & Gynecology (55)
  • Pain Management (1)
  • Pediatrics (98)
    • Cancer (37)
    • Cardiology (3)
    • Child and Adolescent Health (3)
    • (-) Down Syndrome (1)
    • Neuromuscular (5)
  • Psychiatric Disorders (67)
  • Rehabilitation (9)
  • Stroke (7)
  • Surgery (7)
  • Transplant (45)
  • Urology (3)
  • Vascular Conditions (10)
Displaying 1 - 9 of 9

Study of Combinations of REGN2810, Chemotherapy, and Ipilimumab vs. Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer

Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
This study is being done to determine if REGN2810 (anti-PD-1) in combination with ipilimumab (anti-CTLA-4) plus initial platinum-based doublet chemotherapy, or REGN2810 in combination with ipilimumab will prolong how long you live without your disease progressing compared to the standard of care pembrolizumab (anti-PD-1) monotherapy treatment. Neither…
Read More

Lung Cancer Patient Survey Study on Technology Support for Treatment Preparedness

Condition: Cancer / Lung Cancer
Investigator: Alicia Matthews
Status: Closed
We are conducting a survey to gather feedback about lung cancer patients experience with treatment and the challenges you faced. Your insights can help shape better care for future patients and explore how technology can be of help! The survey takes 30-40 minutes, and eligible participants who complete it will receive a gift card. Interested in…
Read More

Impact on Learning and Development in Down Syndrome(CHILD-DS)

Condition: Pediatrics / Down Syndrome
Investigator: Michael DiLorenzo, MD
Status: Closed
Down syndrome (DS) occurs in roughly 1 out of 700 births in the U.S. Half of all children with Down syndrome have congenital heart disease (CHD), often requiring corrective heart surgery. Even though CHD in children without DS is known to be associated with developmental problems, few studies have explored how CHD can affect the development and behavior of…
Read More

Testing Whether the Use of Brain Scans Alone vs. Brain Scans Plus Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

Condition: Cancer / Lung Cancer
Investigator: Simon Cheng, MD, PhD
Status: Closed
We are doing this study because we want to find out if MRI brain scans alone is better or worse than MRI brain scans plus preventative brain radiation for patients with small lung cancer. The usual approach for patients with small cell lung cancer is prophylactic cranial irradiation. If you decide to take part in this study, you will either receive PCI for…
Read More

A Study of Rucaparib as Treatment for Solid Tumors

Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
The experimental drug being investigated in this study is called rucaparib. Rucaparib is being developed by Clovis Oncology, Inc. (the Sponsor), a biopharmaceutical company with headquarters in the United States (US). Rucaparib (trade name: Rubraca) is a medicine that is approved in the European Union (EU) and the US for use in certain types of ovarian…
Read More

Study of VX15/2508 in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors

Condition: Cancer / Solid Tumors
Investigator: Luca Szalontay, MD
Status: Closed
This is a Phase 1/2 multicenter study of VX15/2503 in pediatric patients and young adults with solid tumors which have come back or have not responded to standard therapy. The study treatment is considered experimental because VX15/2503 is not approved by the United States (US) Food and drug Administration (FDA) for treating pediatric patients and young…
Read More

Study of TSR-042 (anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
The study drug (TSR-042) in this study is designed to stop cancer from growing by helping your immune system recognize and fight the cancer. The Study Drug is designed to help your immune system by attaching to a protein called PD-1 and stopping one of the signals that keeps your immune system from recognizing the cancer. This may help your immune system…
Read More

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
This purpose of this study is to determine whether the tumor cells of lung cancer patients contain changes to the DNA sequence of two proteins found on the cells surface- ALK and EGFR. If the tumor contains changes to the DNA of one of these proteins, the patient may be invited to participate on a trial that will look at drugs which may target tumors that…
Read More

Study of SY-1365 in Adult Patients with Advanced Solid Tumors

Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
SY-1365 is an investigational drug that stops the function of a protein known as CDK7. Previous workhas shown that CDK7 is necessary for some cancers to grow. Therefore, SY-1365 could be used to slow down the growth of cancer. This research study is being done to understand the highest tolerated dose of SY-1365, and to assess the safety of SY-1365 in…
Read More
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Terms of Use Privacy Policy ©2026 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science